Express Pharma

Strides Board approves incremental investments in Stelis

It will accelerate Strides’ re-entry into sterile injectables business post the completion of the Company’s non-compete period in December 2019

0 303

Strides Pharma announced that the Board of Directors of the Company have approved an additional investment up to US$ 40 million over a period of 24 months for a controlling stake in Stelis Biopharma.

The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space.

It will also accelerate Strides’ re-entry into sterile injectables business post the completion of the Company’s non-compete period in December 2019.

- Advertisement -